NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial investigates the best dose and side effects of NBTXR3 when given together
with radiation therapy for the treatment of non-small cell lung cancer that cannot be treated
by surgery (inoperable) and has come back (recurrent). NBTXR3 is a radioenhancer designed to
increase the radiotherapy energy dose deposition inside tumor cells. Radiation therapy uses
high energy x-rays to kill tumor cells and shrink tumors. Giving NBTXR3 and radiation therapy
may increase radiation-dependent tumor cell killing without increasing the radiation exposure
of healthy surrounding tissues.